Paper · 2026

[New therapies and ongoing clinical trials in Alzheimer's disease].

Pia Andersen, Alexandre Bonnard, Anne Börjesson‐Hanson, Miia Kivipelto

PubMed, 123 · Published 20 May 2026

View at the publisherCite this paper

In brief

“[New therapies and ongoing clinical trials in Alzheimer's disease].” is a 2026 paper by Pia Andersen and 3 co-authors, published in PubMed. OpenAlex counts 0 citations as of 15 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
0
Authors
4

Abstract

Clinical trials in Alzheimer's disease focus on disease-modifying therapies with targeted approaches addressing underlying pathology. Immunotherapies against amyloid-beta with monoclonal antibodies such as lecanemab and donanemab have shown promise in reducing amyloid plaque burden and modestly preserving cognition and function in early-stage patients. Tau-targeted therapies, including vaccines, antibodies, and antisense oligonucleotides, have indicated good tolerability… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Andersen, P., Bonnard, A., Börjesson‐Hanson, A., & Kivipelto, M. (2026). [New therapies and ongoing clinical trials in Alzheimer's disease]. PubMed, 123. https://pubmed.ncbi.nlm.nih.gov/42159020

MLA 9

Andersen, Pia, et al. “[New therapies and ongoing clinical trials in Alzheimer's disease].” PubMed, vol. 123, 2026. https://pubmed.ncbi.nlm.nih.gov/42159020.

Chicago

Andersen, Pia, Alexandre Bonnard, Anne Börjesson‐Hanson, and Miia Kivipelto. 2026. “[New therapies and ongoing clinical trials in Alzheimer's disease].” PubMed 123. https://pubmed.ncbi.nlm.nih.gov/42159020.

Harvard

Andersen, P. et al. (2026) ‘[New therapies and ongoing clinical trials in Alzheimer's disease].’, PubMed, 123. Available at: https://pubmed.ncbi.nlm.nih.gov/42159020.

IEEE

P. Andersen, A. Bonnard, A. Börjesson‐Hanson, and M. Kivipelto, “[New therapies and ongoing clinical trials in Alzheimer's disease].,” PubMed, vol. 123, 2026.

BibTeX

@article{andersen2026therapies,
  title     = {{[New therapies and ongoing clinical trials in Alzheimer's disease].}},
  author    = {Andersen, Pia and Bonnard, Alexandre and Börjesson‐Hanson, Anne and Kivipelto, Miia},
  journal   = {PubMed},
  year      = {2026},
  volume    = {123},
  url       = {https://pubmed.ncbi.nlm.nih.gov/42159020}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • disease-modifying therapy
  • amyloid-beta immunotherapy
  • lecanemab
  • donanemab
  • tau-targeted therapy
  • antisense oligonucleotides
  • anti-inflammatory therapy

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Andersen, P., Bonnard, A., Börjesson‐Hanson, A., & Kivipelto, M. (2026). [New therapies and ongoing clinical trials in Alzheimer's disease]. PubMed, 123. https://pubmed.ncbi.nlm.nih.gov/42159020

How many times has this paper been cited?

0 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Pia Andersen, Alexandre Bonnard, Anne Börjesson‐Hanson, Miia Kivipelto.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.